CRMD Stock - CorMedix Inc.

CRMD Stock Chart

CRMD Profile

CorMedix Inc., headquartered in Berkeley Heights, New Jersey, is a biopharmaceutical company specializing in the development and commercialization of therapeutic products aimed at combating infectious and inflammatory diseases both in the United States and globally. Founded in 2006, CorMedix is at the forefront of innovation with its lead product candidate, DefenCath/Neutrolin. This novel anti-infective solution is designed to reduce and prevent catheter-related infections and thrombosis in patients requiring central venous catheters across various clinical settings, including hemodialysis, total parenteral nutrition, and oncology.

Formerly known as Picton Holding Company, Inc., CorMedix underwent a name change in January 2007 to reflect its evolving focus on biomedical advancements. The company's commitment to addressing critical medical needs is underscored by its dedication to developing effective therapies that enhance patient outcomes and quality of life.

CorMedix's pioneering approach encompasses rigorous research and development efforts aimed at advancing therapeutic solutions in the healthcare sector. Its strategic initiatives include expanding the application of DefenCath/Neutrolin, exploring new indications, and pursuing regulatory approvals to bring innovative treatments to market. The company leverages its scientific expertise and strategic partnerships to navigate the complex landscape of infectious and inflammatory diseases, ensuring a comprehensive approach to healthcare solutions.

With a focus on improving patient care through innovative biomedical solutions, CorMedix continues to drive forward in its mission to provide effective treatments for critical medical conditions globally. Positioned at the intersection of biotechnology and healthcare, CorMedix remains committed to pioneering new standards in therapeutic efficacy and patient safety.

CRMD Revenue Chart

CRMD Earnings

Analyst Ratings